Alternative Medications to Bupropion for Anhedonia
For anhedonia specifically, consider cariprazine (1.5-3 mg/day) as the most evidence-based alternative to bupropion, with vortioxetine and agomelatine as additional options, while avoiding SSRIs which show poor efficacy for this symptom.
Primary Recommendation: Cariprazine
Cariprazine demonstrates the strongest recent evidence for treating anhedonia across mood disorders. Multiple 2025 studies show specific anti-anhedonic effects that persist even after adjusting for general depressive symptom improvement, indicating this is not merely a pseudospecific effect 1, 2. In patients with major depressive disorder and moderate-to-severe anhedonia (MADRS anhedonia subscale ≥18), cariprazine 1.5 mg/day showed significant improvement in both overall depression (LSMD -3.4, p=0.0006) and anhedonia-specific symptoms (LSMD -2.1, p=0.0010) compared to placebo 1.
Dosing Algorithm for Cariprazine:
- Start: 1.5 mg/day orally
- Target dose: 1.5-3 mg/day based on response
- Timeline: Assess at 6 weeks
- Note: The 1.5 mg dose shows more consistent anti-anhedonic effects across anhedonia severity levels 1, 2
Secondary Options
Vortioxetine
A 2025 narrative review identifies vortioxetine as having promising anti-anhedonic effects, superior to traditional SSRIs 3. This multimodal antidepressant targets multiple serotonin receptors and may address reward processing deficits more effectively than selective reuptake inhibition alone.
Agomelatine
Melatonergic agents, particularly agomelatine, show beneficial effects on anhedonia measures in systematic reviews 4. The unique mechanism targeting melatonin receptors and 5-HT2C antagonism may help restore circadian-related reward processing.
Dextromethorphan-Bupropion Combination
For patients with dual diagnosis (depression plus substance use disorder), the dextromethorphan-bupropion combination shows promise through synergistic glutamatergic and dopaminergic mechanisms 5. This represents an evolution beyond bupropion monotherapy, though evidence remains limited to case series.
What to Avoid
SSRIs and SNRIs show poor efficacy for anhedonia specifically 3. While they may improve general depressive symptoms, they often leave anhedonic symptoms unresolved. Escitalopram combined with riluzole was specifically ineffective for anhedonia in controlled trials 4.
Clinical Context from Bupropion Evidence
Bupropion itself is described as "activating" with "possible rapid improvement of energy level" in older guidelines 6. The FDA label confirms it works through dopamine/norepinephrine reuptake inhibition 7. When seeking alternatives, you're looking for medications that similarly target dopaminergic reward pathways or use complementary mechanisms.
Key Contraindications to Screen For:
- Seizure history or risk factors (brain metastases, eating disorders, alcohol withdrawal) - these contraindicate bupropion and should guide alternative selection 8, 7
- Uncontrolled hypertension - relevant for both bupropion and naltrexone-bupropion combinations 9
- Concurrent opioid use - contraindicates naltrexone-containing combinations 9
Emerging Treatments
Ketamine and psilocybin show anti-anhedonic effects in recent research 3, 10, 4, though these remain investigational for routine clinical use. Kappa-opioid receptor antagonists (like aticaprant) represent novel targets under investigation 3, 10.
Practical Algorithm
- First-line alternative: Cariprazine 1.5 mg/day, titrate to 3 mg/day if needed
- If cariprazine unavailable or not tolerated: Vortioxetine or agomelatine
- If comorbid substance use disorder: Consider dextromethorphan-bupropion combination
- Avoid: SSRI monotherapy for anhedonia-predominant presentations
Critical Pitfall
The most common error is treating anhedonia with SSRIs expecting symptom resolution. Anhedonia requires mechanistically distinct approaches - dopaminergic, glutamatergic, or multimodal agents rather than purely serotonergic interventions 3, 4. Routine assessment of anhedonia as a distinct symptom domain (not just general depression severity) is essential for treatment selection and monitoring 3.